2024-512939-67-00
Recruiting
Phase 1
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants
Mindstate Design Labs Inc.1 site in 1 country68 target enrollmentMay 22, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Mindstate Design Labs Inc.
- Enrollment
- 68
- Locations
- 1
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Paul Wren
Scientific
Mindstate Design Labs Inc.
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR2023-507667-19-00Novartis Pharma AG24
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma2023-505212-38-00Genentech Inc.43
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Standard-of-Care Chemotherapy in Patients with Locally Advanced or Metastatic Solid Tumors2022-502615-11-00Genentech Inc., Genentech Inc.35
Recruiting
Phase 1
Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients2023-507075-22-00Eurofins Optimed, Perha Pharmaceuticals120
Recruiting
Not Applicable
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal SprayNCT07259538VivaVision Biotech, Inc60